Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Recruiting

Phase 2

Phase 3

DeutetrabenazineImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Sponsor:

Vanderbilt University Medical Center

Code:

NCT04713982

Conditions

Huntington Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Deutetrabenazine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Vanderbilt University Medical Center on 2025-02-13.